Market News How it works Learn FAQ
| RCT 0.0796 4.60% | NU 12.69 -16.29% | EWZ 34.43 -19.16% | BBD 2.935 -27.89% | TGL 0.2399 8.31% | AZTR 1.6199 126.56% | ITUB 7.75 -19.86% | NVD 3.9801 -5.01% | XP 15.9 -47.71% | SRTM 0.2985 -30.63% | WFF 0.0918 14.75% | SHFS 0.0943 -28.78% | SPCX 148.07 0.39% | PBR 22.515 -13.93% | SOXL 92.02 10.12% | VALE 11.96 -3.55% | CLRO 5.015 54.31% | INTC 91.38 5.08% | TSLL 10.875 11.42% | NVDA 216.37 2.56% | GCDT 0.1444 -18.00% | NOK 8.735 7.31% | NWGL 0.089 8.54% | BITO 10.66 -1.57% | SOXS 47.14 -10.14% | CRWV 56.4528 4.09% | RWM 14.485 -0.45% | JBLU 2.345 -10.67% | GPUS 0.1808 7.05% | ABEV 2.835 -14.09% | TSLG 5.44 11.70% | SGRY 23.245 47.59% | AAL 12.2501 1.16% | IREN 25.945 4.18% | INTR 4.6799 -34.91% | SBS 4.69 -26.72% | QID 14.175 -2.58% | TQQQ 68.805 3.79% | RBNE 0.17 -10.53% | T 20.9 -0.14% | SPDN 8.485 -0.64% | TSLA 393.715 5.77% | RIG 6.455 0.70% | WULF 12.225 7.99% | NFLX 63.745 -3.20% | SID 0.9078 -23.07% | LUCD 0.52 26.52% | GRAB 2.692 -3.51% | XTND 2.235 26.27% | PLUG 1.39 0.72%
TRFirst Tracks Biotherapeutics Inc logo

First Tracks Biotherapeutics Inc (TRAX)

NASDAQ Global Select · Currency in USD
$43.48 ▼ -0.57 (-1.29%)
At close: Oct 26, 4:00 PM ET. Market closed.
$43.48 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:04 PM ET

Summary

Previous Close
$44.05
Open
$43.10
Day's Range
$41.83 – $45.42
52 Week Range
$14.72 – $49.91
Volume
567,849
Avg. Volume
888,934
Market Cap
$1.55B
Beta (5Y Monthly)
3.37
PE Ratio (TTM)
--
EPS (TTM)
-$3.57
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$71.33

Profile: First Tracks Biotherapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
104
CEO
Daniel R. Faga

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.92
DateEst.Actual
Aug 12, 2026-$0.80-$0.95Miss
May 14, 2026-$0.98-$1.45Miss

Analyst view

Consensus price target
$71.33 ▲ +64.1%
Range $57.00 – $100.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on TRAX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.